Roche Amplicor HPV test
This article was originally published in The Gray Sheet
Executive Summary
Roche study comparing Amplicor with Digene's Hybrid Capture 2 test suggests Amplicor may be more sensitive, according to Jane Gibson, PhD, molecular genetics director at the AmeriPath Center for Advanced Diagnostics in Orlando. Presented at the 21st International Papillomavirus Conference in Mexico City, the results reveal an HPV-positive rate of 15.1% with Amplicor and 9.3% with the HC2 test. The presence of high-risk HPV was confirmed in 33% of Amplicor positive/HC2 negative specimens. Roche plans to complete U.S. clinical trials of the polymerase-chain reaction test by Q2 2005 (1"The Gray Sheet" Feb. 9, 2004, p. 14)...
You may also be interested in...
Roche HPV assay
FDA initiates dialogue with company over classification of HPV assay as analyte-specific reagent, according to Roche, which said it plans to meet with agency officials within days. In November, FDA informed the firm that the AmpliChip microarray requires clearance prior to marketing and cannot be offered to labs as an ASR for determining drug metabolization rates. Roche has removed all information pertaining to the HPV test from its website, including a release citing claims by Jane Gibson, PhD, that the product could be more sensitive than hybrid capture technology currently on the market (1"The Gray Sheet" March 1, 2004, In Brief)...
Roche Amplicor HPV Test To Battle With Digene: A David & Goliath Scenario?
Roche Diagnostics' plan to obtain a CE mark by the second quarter for its Amplicor human papillomavirus PCR-based test and complete U.S. trials by Q2 2005 has Digene scurrying to maintain its DNAwithPap first-to-market advantage
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.